

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS	17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAPLUS
NEWS	18	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS	19	JAN 25	Annual Reload of MEDLINE database
NEWS	20	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS	21	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS	22	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS	23	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS	24	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:53:25 ON 17 MAR 2010

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 16:53:38 ON 17 MAR 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAR 2010 HIGHEST RN 1210608-68-6

DICTIONARY FILE UPDATES: 16 MAR 2010 HIGHEST RN 1210608-68-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10758589\_NEW.str



```

chain nodes :
7  8  9 10 11 12 13 14 15 22 23 24 25 26 27
ring nodes :
1  2  3  4  5  6 16 17 18 19 20 21
chain bonds :
6-7  7-8  7-24  8-9  8-26  9-10 10-11 10-22 11-12 12-13 12-23 13-14 14-15
14-27 15-16 15-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21
exact/norm bonds :
7-8  7-24  8-9  9-10 10-22 12-13 12-23 13-14 14-15 15-25
exact bonds :
6-7  8-26 10-11 11-12 14-27 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom
19:Atom 20:Atom 21:Atom 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS


```

L1 STRUCTURE UPLOADED

```

=> d l1
L1 HAS NO ANSWERS
L1 STR

```



Structure attributes must be viewed using STN Express query preparation.

```

=> s l1 sss
SAMPLE SEARCH INITIATED 16:54:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 15 TO ITERATE

100.0% PROCESSED          15 ITERATIONS                2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   68 TO   532


```

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> d 12 1-2


L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 1008758-35-7 REGISTRY  
ED Entered STN: 18 Mar 2008  
CN Propanedioic acid, 1,3-bis[2-[(4-methoxyphenyl)thioxomethyl]-2-methylhydrazide], potassium salt (1:2) (CA INDEX NAME)  
MF C21 H24 N4 O4 S2 . 2 K  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
CRN (488832-83-3)



● 2 K

5 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 488833-02-9 REGISTRY  
ED Entered STN: 12 Feb 2003  
CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Propanedioic acid, bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (9CI)  
DR 1008757-56-9  
MF C23 H28 N4 O2 S2  
CI COM  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l1 exa  
SAMPLE SEARCH INITIATED 16:54:44 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 0 TO 0  
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA EXA SAM L1

=> s l1 full  
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 16:54:50 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 389 TO ITERATE

100.0% PROCESSED 389 ITERATIONS 102 ANSWERS  
SEARCH TIME: 00.00.01

L4 102 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 196.23 196.45

FILE 'CAPLUS' ENTERED AT 16:54:56 ON 17 MAR 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Mar 2010 VOL 152 ISS 12  
FILE LAST UPDATED: 16 Mar 2010 (20100316/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 14
L5          36 L4

=> s 15 and (?cancer? or ?tumor? or ?tumour? or ?neoplasm?)/ti
215565 ?CANCER?/TI
188206 ?TUMOR?/TI
6861 ?TUMOUR?/TI
6861 ?TUMOUR?/TI
194994 ?TUMOR?/TI
      ((?TUMOR? OR ?TUMOUR?)/TI)
6861 ?TUMOUR?/TI
188206 ?TUMOR?/TI
188206 ?TUMOR?/TI
194994 ?TUMOUR?/TI
      ((?TUMOUR? OR ?TUMOR?)/TI)
5017 ?NEOPLASM?/TI
L6          11 L5 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)/TI
```

```
=> dup rem 16
PROCESSING COMPLETED FOR L6
L7          11 DUP REM L6 (0 DUPLICATES REMOVED)
```

```
=> d 17 1-11 ibib abs
```

```
L7  ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:      2009:707534  CAPLUS
DOCUMENT NUMBER:       151:42041
TITLE:                 Polymorphs of N-malonyl-bis(N'-methyl-N'-
                        thiobenzoylhydrazide) and compositions for treatment
                        of cancer
INVENTOR(S):           Kostik, Elena I.; Sun, Lijun; Dziewieszek, Joanna;
                        Choi, Jun Y.
PATENT ASSIGNEE(S):    Synta Pharmaceuticals Corp., USA
SOURCE:                PCT Int. Appl., 100pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:         Patent
LANGUAGE:              English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009073148	A2	20090611	WO 2008-US13204	20081128
WO 2009073148	A3	20091015		

```
W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
    CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
    FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
    KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
    ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
    PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
    TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
    IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
    TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
    TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
    AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
```

```
PRIORITY APPLN. INFO.:      US 2007-4476P      P  20071128
                             US 2007-4740P      P  20071129
```

```
AB  The invention relates to crystalline forms of
    N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide) (Compound 1). At least 70%
    by weight of Compound 1 is the single crystalline form, Form A, Form C, or
    Form D of
```

the compound A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent, and Compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D of

compound is provided. A method of treating a subject with cancer, especially melanoma, comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition thereof, in combination with an effective amount of paclitaxel or a paclitaxel analog. Thus, 5 g of Compound 1 was dissolved in 1350 mL of dichloromethane, cooled to 0° and agitated for 12-16 h. The resulting solid was filtered, washed and dried to give Form C of Compound 1 (yield 3-3.5 g).

L7 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:831279 CAPLUS

DOCUMENT NUMBER: 149:160584

TITLE: Method for treating cancer comprising administering compound that increases oxidative stress of cancer cells and activates p38

INVENTOR(S): Betin, John; Kirshner, Jessica R.; Du, Zhenjian

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 124pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2008082579	A1	20080710	WO 2007-US26343	20071227
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


US 20090093538 A1 20090409 US 2007-5654 20071227

PRIORITY APPLN. INFO.: US 2007-878557P P 20070103

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:160584

GI



AB The invention relates to a method of treating cancer in a subject, comprising administering to the subject an anti-cancer therapy and a compound that increases the oxidative stress of the cancer cells and

activates p38, such as compound (I). It is related to the discovery that the efficacy of standard treatments for cancer, such as chemotherapy or radiation treatment, can be increased by administering them in combination with an agent that increase the oxidative stress of cancer cells by inhibiting the mechanisms that cancer cells utilize to compensate for ROS and/or activating cellular signaling pathways that lead to immunocytotoxicity. Thus, formulation comprising paclitaxel (5 mg/kg) + compound I (50 mg/kg) significantly enhanced antitumor activity of paclitaxel on human breast tumor MDA-MB-435 in nude mice, without increasing toxicity.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:285694 CAPLUS

DOCUMENT NUMBER: 148:299878

TITLE: Combination with bis(thiohydrazide amides) for treating cancer

INVENTOR(S): Koya, Keizo

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 125pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008027445	A2	20080306	WO 2007-US19021	20070830
WO 2008027445	A3	20080626		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007290490	A1	20080306	AU 2007-290490	20070830
US 20080119440	A1	20080522	US 2007-897538	20070830
EP 2076254	A2	20090708	EP 2007-837506	20070830
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2010502616	T	20100128	JP 2009-526701	20070830
PRIORITY APPLN. INFO.:			US 2006-841570P	P 20060831
			WO 2007-US19021	W 20070830

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 148:299878

AB Disclosed herein are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with hyperthermia treatment. Also disclosed are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with radiotherapy.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD



## (1 CITINGS)

L7 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
 ACCESSION NUMBER: 2008:256009 CAPLUS  
 DOCUMENT NUMBER: 148:299872  
 TITLE: Bis(thiohydrazide amide) combination with  
 immunotherapy for treating cancer  
 INVENTOR(S): Jacobson, Eric  
 PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
 SOURCE: PCT Int. Appl., 143pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008024299	A2	20080228	WO 2007-US18354	20070820
WO 2008024299	A3	20080417		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007288334	A1	20080228	AU 2007-288334	20070820
EP 2059236	A2	20090520	EP 2007-811430	20070820
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2010501558	T	20100121	JP 2009-525581	20070820
PRIORITY APPLN. INFO.:			US 2006-839113P	P 20060821
			WO 2007-US18354	W 20070820

OTHER SOURCE(S): MARPAT 148:299872

AB The invention discloses methods for treating an immunosensitive cancer with bis(thiohydrazide amides), or pharmaceutically acceptable salts thereof, and an immunotherapy. Compds. of the invention include e.g. PhC(S)N(Me)NHC(O)CH<sub>2</sub>C(O)NHN(Me)C(S)Ph.

L7 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
 ACCESSION NUMBER: 2008:1017205 CAPLUS  
 DOCUMENT NUMBER: 149:282666  
 TITLE: Elesclomol induces cancer cell apoptosis  
 through oxidative stress  
 AUTHOR(S): Kirshner, Jessica R.; He, Suqin; Balasubramanyam, Vishwasenani; Kepros, Jane; Yang, Chin-Yu; Zhang, Mei; Du, Zhenjian; Barsoum, James; Bertin, John  
 CORPORATE SOURCE: Synta Pharmaceuticals Corp., Lexington, MA, 02421, USA  
 SOURCE: Molecular Cancer Therapeutics (2008), 7(8), 2319-2327  
 CODEN: MCTOCF; ISSN: 1535-7163  
 PUBLISHER: American Association for Cancer Research  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Elesclomol (formerly STA-4783) is a novel small mol. undergoing clin. evaluation in a pivotal phase III melanoma trial (SYMMETRY). In a phase

II randomized, double-blinded, controlled, multi-center trial in 81 patients with stage IV metastatic melanoma, treatment with elesclomol plus paclitaxel showed a statistically significant doubling of progression-free survival time compared with treatment with paclitaxel alone. Although elesclomol displays significant therapeutic activity in the clinic, the mechanism underlying its anticancer activity has not been defined previously. Here, we show that elesclomol induces apoptosis in cancer cells through the induction of oxidative stress. Treatment of cancer cells in vitro with elesclomol resulted in the rapid generation of reactive oxygen species (ROS) and the induction of a transcriptional gene profile characteristic of an oxidative stress response. Inhibition of oxidative stress by the antioxidant N-acetylcysteine blocked the induction of gene transcription by elesclomol. In addition, N-acetylcysteine blocked drug-induced apoptosis, indicating that ROS generation is the primary mechanism responsible for the proapoptotic activity of elesclomol. Excessive ROS production and elevated levels of oxidative stress are critical biochem. alterations that contribute to cancer cell growth. Thus, the induction of oxidative stress by elesclomol exploits this unique characteristic of cancer cells by increasing ROS levels beyond a threshold that triggers cell death. [Mol Cancer Ther 2008;7(8):2319-27].

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:87076 CAPLUS

DOCUMENT NUMBER: 146:330123

TITLE: Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors

AUTHOR(S): Berkenblit, Anna; Eder, Joseph P., Jr.; Ryan, David P.; Seiden, Michael V.; Tatsuta, Noriaki; Sherman, Matthew L.; Dahl, Thomas A.; Dezube, Bruce J.; Supko, Jeffrey G.

CORPORATE SOURCE: Beth Israel Deaconess Medical Center, Boston, MA, USA

SOURCE: Clinical Cancer Research (2007), 13(2, Pt. 1), 584-590

CODEN: CCREF4; ISSN: 1078-0432

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB STA-4783 is a new compound that markedly enhances the therapeutic index of paclitaxel against human tumor xenograft models. A phase I clin. trial was undertaken to determine the maximum tolerated dose, toxicity profile, and pharmacokinetics of STA-4783 in combination with paclitaxel. Adults with refractory solid tumors concurrently received STA-4783 and paclitaxel as a 3-h i.v. infusion at starting doses of 44 and 135 mg/m<sup>2</sup>, resp. After increasing paclitaxel to 175 mg/m<sup>2</sup>, the STA-4783 dose was escalated as permitted by dose-limiting toxicity during the first 21-day cycle. Thirty-five patients were treated with eight dose levels of STA-4783/paclitaxel. In patients receiving 175 mg/m<sup>2</sup> paclitaxel, the incidence of severe toxicity increased with escalation of the STA-4783 dose above 263 mg/m<sup>2</sup>, and 438 mg/m<sup>2</sup> was the maximum tolerated dose. All toxicities were typical of paclitaxel, with neutropenia, mucositis, and myalgia/arthralgia being dose limiting. Partial responses were achieved in one patient with Kaposi's sarcoma and another with ovarian cancer that progressed during prior treatment with paclitaxel. STA-4783 exhibited linear pharmacokinetics characterized by rapid elimination from plasma (biol. half-life, 1.06 ± 0.24 h) and a low steady-state apparent volume of distribution (25.1 ± 8.1 L/m<sup>2</sup>). The total body clearance of paclitaxel decreased significantly with escalation of the STA-4783 dose. The STA-4783/paclitaxel combination was well tolerated with a toxicity

profile similar to single-agent paclitaxel. Enhanced systemic exposure to paclitaxel resulting from a dose-dependent interaction with STA-4783 was associated with increased toxicity. Objective responses in two heavily pretreated patients, both with taxane exposure, have encouraged further clin. evaluation of this regimen.

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:1122626 CAPLUS

DOCUMENT NUMBER: 145:449186

TITLE: Combination cancer therapy with bis(thiohydrazide) amide compounds and taxanes

INVENTOR(S): Dahl, Thomas A.; McLeod, Matthew

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 63pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113695	A1	20061026	WO 2006-US14531	20060413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006236378	A1	20061026	AU 2006-236378	20060413
CA 2604907	A1	20061026	CA 2006-2604907	20060413
EP 1877048	A1	20080116	EP 2006-750538	20060413
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008536875	T	20080911	JP 2008-506821	20060413
ZA 2007008703	A	20081126	ZA 2007-8703	20071011
MX 2007012688	A	20080314	MX 2007-12688	20071012
US 20090137682	A1	20090528	US 2008-918357	20080825
PRIORITY APPLN. INFO.:			US 2005-672139P	P 20050415
			WO 2006-US14531	W 20060413

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 145:449186

AB A method of treating a subject with cancer includes co-administering to the subject over 3-5 wk, a taxane in an amount of between about 243-315  $\mu\text{mol/m}^2$  (e.g., equivalent to paclitaxel in about 210-270  $\text{mg/m}^2$ ); and a bis(thiohydrazide amide) in an amount between about 1473-1722  $\mu\text{mol/m}^2$ . (e.g.  $\text{PhC(S)N(Me)NHC(O)CH}_2\text{C(O)NHN(Me)C(S)Ph}$  in about 590-690  $\text{mg/m}^2$ ). The bis(thiohydrazide amide) is represented by  $\text{R1C(S)N(R3)N(R7)C(Z)YC(Z)N(R8)N(R4)C(S)R2}$  [Y = covalent bond, (un)substituted straight chain hydrocarbyl, or C(Z)YC(Z) forms (un)substituted aromatic group; R1-R4 = H, (un)substituted aliphatic group,

(un)substituted aryl group, etc.; R7, R8 = H, (un)substituted aliphatic group, (un)substituted aryl group; Z = O, S].  
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 2006:1124931 CAPLUS  
DOCUMENT NUMBER: 145:449193  
TITLE: Natural killer cell activity-based methods for determining prognosis for patients undergoing cancer therapy  
INVENTOR(S): Barsoum, James; Du, Zhenjian; Dahl, Thomas A.; McLeod, Matthew  
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
SOURCE: PCT Int. Appl., 82 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113493	A2	20061026	WO 2006-US14186	20060413
WO 2006113493	A3	20081231		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2005-671833P P 20050415  
OTHER SOURCE(S): MARPAT 145:449193  
AB A method of determining a prognosis for a subject undergoing cancer therapy with  
an agent that activates heat shock protein 70 (Hsp70) includes comparing natural killer (NK) cell activity in a test sample with NK cell activity in a control sample. The control sample can be taken from the subject before dosing with the agent and the test sample can be taken from the subject after dosing with the agent. An increase in NK cell activity in the test sample compared with the control sample can indicate an improved prognosis.  
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L7 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 2006:75829 CAPLUS  
DOCUMENT NUMBER: 144:170795  
TITLE: Preparation of bis(thiohydrazide amide) salts for treatment of cancer  
INVENTOR(S): Kostik, Elena; Vaghefi, Farid; Liang, Guiqing; Koya, Keizo; Sun, Lijun; Tatsuta, Noriaki; Chen, Shoujun; Inoue, Takayo; Xia, Zhi-Qiang  
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
SOURCE: PCT Int. Appl., 101 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006009940	A1	20060126	WO 2005-US21642	20050620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005265202	A1	20060126	AU 2005-265202	20050620
AU 2005265202	B2	20090723		
CA 2570698	A1	20060126	CA 2005-2570698	20050620
US 20060135595	A1	20060622	US 2005-157213	20050620
US 7385084	B2	20080610		
EP 1781604	A1	20070509	EP 2005-762347	20050620
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
CN 1993318	A	20070704	CN 2005-80026445	20050620
JP 2008504264	T	20080214	JP 2007-518152	20050620
BR 2005012526	A	20080311	BR 2005-12526	20050620
NZ 552159	A	20091224	NZ 2005-552159	20050620
ZA 2006010440	A	20071227	ZA 2006-10440	20061213
MX 2006015126	A	20080911	MX 2006-15126	20061220
IN 2007DN00172	A	20070803	IN 2007-DN172	20070108
NO 2007000378	A	20070316	NO 2007-378	20070119
KR 2007029259	A	20070313	KR 2007-701513	20070122
US 20080269340	A1	20081030	US 2008-148312	20080418
US 7579503	B2	20090825		
US 20090281172	A1	20091112	US 2009-503661	20090715
PRIORITY APPLN. INFO.:			US 2004-582596P	P 20040623
			US 2005-681368P	P 20050516
			US 2005-157213	A1 20050620
			WO 2005-US21642	W 20050620
			US 2008-148312	A1 20080418

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 144:170795

AB R1CSNR3N:C(Z-)YC(Z-):NNR4CSR2.2M+ [Y = bond, (substituted) hydrocarbylene; R1-R4 = H, (substituted) aliphatic, aryl; R1R3, R2R4 = atoms to form non-aromatic heterocyclic ring optionally fused to aromatic ring; Z = O, S; M+

=



pharmaceutically acceptable cation], were prepared Thus, (PhCSNMeNHCO)2CH2 was added to aqueous NaOH followed by freeze drying to give [PhCSNMeN:C(ONa)]2CH2. The latter showed H2O soly of >1000 mg/mL.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

DOCUMENT NUMBER: 141:173877  
 TITLE: A preparation of malonyl dihydrazide derivatives,  
 useful for the treatment of multi-drug resistant  
 cancer  
 INVENTOR(S): Koya, Keizo; Sun, Lijun; Wu, Yaming; Korbut, Timoty;  
 Zhou, Dan; Du, Zhenjian; Chen, Shoujun; Tatsuta,  
 Noriaki; Liang, Guiqing; Ono, Mitsunori  
 PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
 SOURCE: PCT Int. Appl., 113 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064826	A1	20040805	WO 2004-US1089	20040115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004206865	A1	20040805	AU 2004-206865	20040115
AU 2004206865	B2	20060713		
CA 2512797	A1	20040805	CA 2004-2512797	20040115
US 20040225016	A1	20041111	US 2004-758589	20040115
EP 1583524	A1	20051012	EP 2004-702560	20040115
EP 1583524	B1	20060823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515626	T	20060601	JP 2006-500976	20040115
AT 336991	T	20060915	AT 2004-702560	20040115
PT 1583524	E	20061229	PT 2004-702560	20040115
ES 2271839	T3	20070416	ES 2004-702560	20040115
HK 1084024	A1	20070119	HK 2006-104252	20060407
AU 2006228035	A1	20061102	AU 2006-228035	20061011
AU 2006228035	B2	20100218		
PRIORITY APPLN. INFO.:			US 2003-440406P	P 20030115
			AU 2004-206865	A3 20040115
			WO 2004-US1089	W 20040115
OTHER SOURCE(S):			MARPAT 141:173877	
GI				



AB One embodiment of the present invention is a method of treating a subject with a multi-drug resistant cancer. The method comprises administering to the subject an effective amount of a compound represented by formula I [wherein: Y is a covalent bond or (un)substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is (un)substituted aromatic group; R1-R4 are independently H, aliphatic group, substituted aliphatic group, or aryl group, etc.; R5 and R6 are independently H, aliphatic group, substituted aliphatic group, (un)substituted aryl group; Z is O or S]. For instance, malonyl dihydrazide derivative II (IC50 = 0.005  $\mu$ M, multi-drug cell line MES-SA/DX5) was prepared via amidation of malonic acid by PhC(:S)N(Me)NH2 with a yield of 80% (example 4).

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:818151 CAPLUS

DOCUMENT NUMBER: 139:323341

TITLE: Preparation of thiobenzoylhydrazide derivatives as taxol enhancers for treatment of cancer

INVENTOR(S): Koya, Keizo; Sun, Lijun; Chen, Shoujun; Tatsuta, Noriaki; Wu, Yaming; Ono, Mitsunori

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 193,075.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030195258	A1	20031016	US 2003-345885	20030115
US 6924312	B2	20050802		
US 20030045518	A1	20030306	US 2002-193639	20020710
US 6762204	B2	20040713		
US 20030119914	A1	20030626	US 2002-193075	20020710
US 6800660	B2	20041005		
EP 1731148	A1	20061213	EP 2006-19066	20020710
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI				
EP 2100605	A1	20090916	EP 2009-4577	20020710
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI				
ZA 2004001051	A	20050622	ZA 2004-1051	20040209
ZA 2004001054	A	20050622	ZA 2004-1054	20040209
US 20040235909	A1	20041125	US 2004-803798	20040318
US 7001923	B2	20060221		
US 20050009920	A1	20050113	US 2004-846152	20040514
US 7037940	B2	20060502		
US 20060116374	A1	20060601	US 2005-244427	20051005
US 7368473	B2	20080506		
US 20060122183	A1	20060608	US 2005-244324	20051005
US 7345094	B2	20080318		
US 20080214655	A1	20080904	US 2008-9641	20080118
US 7671092	B2	20100302		
US 20080242702	A1	20081002	US 2008-77729	20080320
PRIORITY APPLN. INFO.:			US 2001-304252P	P 20010710

US 2002-361936P	P	20020306
US 2002-361946P	P	20020306
US 2002-193075	A2	20020710
US 2002-193639	A2	20020710
EP 2002-746947	A3	20020710
EP 2002-752238	A3	20020710
US 2004-803798	A1	20040318
US 2004-846152	A1	20040514
US 2005-244324	A1	20051005
US 2005-244427	A3	20051005

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): MARPAT 139:323341  
 GI



AB The title compds. I [wherein Y = a single bond, phenylene, or (un)substituted hydrocarbyl, etc.; R1 and R2 = independently (un)substituted aryl; R3-R6 = independently H, (un)substituted aliphatic group, or aryl; Z = O or S; etc.] and pharmaceutically acceptable salts thereof are prepared as taxol enhancers for treatment of cancer. For example, the compound II was prepared in a multi-step synthesis. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of I in combination with taxol or an analog of taxol. II showed synergistic anticancer activity with paclitaxel in rat.

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD  
 (10 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 16:53:25 ON 17 MAR 2010)

FILE 'REGISTRY' ENTERED AT 16:53:38 ON 17 MAR 2010

L1	STRUCTURE UPLOADED
L2	2 S L1 SSS
L3	0 S L1 EXA
L4	102 S L1 FULL

FILE 'CAPLUS' ENTERED AT 16:54:56 ON 17 MAR 2010

L5	36 S L4
L6	11 S L5 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)/TI
L7	11 DUP REM L6 (0 DUPLICATES REMOVED)

=>

---Logging off of STN---



=>  
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	44.34	240.79
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-9.35	-9.35

STN INTERNATIONAL LOGOFF AT 16:56:14 ON 17 MAR 2010